The FY23 Defense Appropriations Act provides funding for the Bone Marrow Failure Research Program to support innovative, high-impact bone marrow failure research. The managing agent for the anticipated funding opportunities is the CDMRP at the U.S. Army Medical Research and Development Command.
Qure.ai has announced the completion of a $65 million Series D funding round. The investment will expedite expansion into the U.S. market and other countries, increase investment in foundational AI models, and enable complementary med-tech company acquisitions.
